Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients.

Overview

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

Full Title of Study: “A Phase II Trial to Evaluate the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 11, 2027

Detailed Description

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in 24 peanut allergic patients, 12-17 years of age. After reacting to <=100 mg peanut protein during initial DBPCFC, patients will be randomized to receive either oral Vancomycin and Neomycin or placebo/placebo for 7 days. Patients will then come to the Experimental and Therapeutic Unit (ETU) to receive orally 5 capsules of MTT or placebo under medical supervision. Patients will then take 2 capsules of MTT or placebo daily for 27 days. Patients will return to the ETU to undergo a second DBPCFC within 2 weeks of end of MTT/placebo treatment and 4 months post MTT initiation. They will return to the ETU for an exit visit 6 months after end of treatment. Gut microbiota will be analyzed serially using state-of-the-art 16SRNA sequencing prior to transplantation, then at 4 weeks, 4-month, and 6 months post transplantation. Immunological biomarkers and mechanistic studies will be performed on blood taken at baseline, second DBPCFC visit and exit visit. Adverse events will be monitored carefully throughout the study.

Interventions

  • Biological: Microbial Transplantation Therapy / Placebo
    • Subjects will be administered oral MTT capsules or placebo over the course of 28 days.

Arms, Groups and Cohorts

  • Experimental: antibiotic / MTT
    • Study subjects randomized to the experimental arm will receive oral antibiotics for 7 days as a way to modulate the composition of the gastrointestinal microbiota. Upon completion of oral antibiotics, subjects randomized to the experimental arm will be administeredf MTT under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take MTT capsules daily for 27 days.
  • Active Comparator: placebo / placebo
    • Study subjects randomized to the placebo arm will receive oral placebo capsules instead of oral antibiotics, for 7 days, at the same frequency and capsule amount per dose. Upon completion of 7 days of placebo (matching the antibiotics given in the experimental arm), subjects randomized to the placebo arm will be administered capsules of placebo (matching the MTT capsules given in the experimental arm) under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take placebo capsules daily for 27 days.

Clinical Trial Outcome Measures

Primary Measures

  • Changes in threshold of peanut reactivity during DBPCFC (<=100 mg to 300 mg peanut protein)
    • Time Frame: 4 months post MTT
    • Changes in threshold of peanut reactivity during DBPCFC after 28 days of MTT from <=100 mg to 300 mg peanut protein and 4 months post therapy initiation.

Secondary Measures

  • Changes in threshold of peanut reactivity during DBPCFC (<=100 mg to 600 mg peanut protein)
    • Time Frame: 4 months post MTT
    • Changes in threshold of peanut reactivity during DBPCFC after 28 days of MTT from <=100 mg to 600 mg peanut protein and 4 months post therapy initiation.
  • Adverse Events
    • Time Frame: 8 months
    • MTT Treatment emergent adverse events
  • Changes in Skin Test Wheal Size and IgE level
    • Time Frame: 8 months
    • Changes in skin test peanut specific wheal size, peanut-specific IgE level over time
  • Changes in Gut Microbial Composition
    • Time Frame: 8 months
    • Changes in gut microbial composition and persistence of that change over time
  • Changes in Biomarkers
    • Time Frame: 8 months
    • Changes in biomarkers including RoRgt+Treg cells and Th2 helper cells frequencies after MTT therapy

Participating in This Clinical Trial

Inclusion Criteria

1. Develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United States/European Union Initiative) guidelines at 1 mg, 3 mg, 10 mg, 30 mg, or 100 mg peanut protein. 2. Has a positive SPT to peanut (≥3mm) and/or a positive peanut-specific IgE >0.35kU/L. 3. For asthmatic patients, has a Spirometry or Peak Flow with Measurement of FEV1>=80% of predicted 4. Has a negative urine hCG test if a female participant. 5. Agrees to use an acceptable single-barrier form of birth control from enrollment through the exit DBPCFC study visit if female of childbearing potential and sexually active. An example of a single-barrier method of contraception includes condoms or oral contraceptives. Acceptable methods of birth control include implants, injectables, combined oral contraceptives, some intrauterine contraceptive devises (IUDs), sexual abstinence, a vasectomized partner, the contraceptive patch, the contraceptive ring, and condoms. 6. Able to swallow 2 empty capsules size 00. 7. Able to give informed assent and guardian willing to give informed consent. 8. Willing and able to participate in the study requirements, including study visits, DBPCFCs, serial stool collection 9. Willing to undergo telephone or email follow-up to assess for safety and adverse events. Exclusion Criteria:

1. Patients with a history of severe anaphylaxis to any food (hypotension requiring vasopressor support, hypoxia requiring mechanical ventilation, or neurological compromise) 2. Patients with a history of IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of these l food estimated to be above the LOAEL in 5 capsules combined, and excluding oral allergy syndrome). 3. Patients with chronic illness other than controlled asthma that is mild intermittent, mild- persistent or moderate persistent, mild eczema and allergic rhinitis. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment. 4. Recurrent or chronic infections necessitating frequent systemic (including oral) antibiotic administration. 5. Patients on chronic systemic immunosuppressive therapies. 6. Patients who are diagnosed with active, chronic urticaria. 7. Patients who have received peanut oral immunotherapy within the past 6 months. 8. Patients who are on the up-dosing phase of aeroallergen immunotherapy or patients who have received Omalizumab or dupilumab therapy within the past 6 months. 9. Women who are pregnant or breast feeding or planning to get pregnant during the time of the study. 10. Sexually active female patients who refuse to use contraception from enrollment through the third DBPCFC study visit 11. Patient with GI conditions including inflammatory bowel disease, eosinophilic esophagitis, food protein induced enterocolitis, uncontrolled reflux despite medication, uncontrolled chronic constipation despite medication, esophageal dysmotility, swallowing dysfunction, delayed gastric emptying syndromes, pill esophagitis or history of aspiration pneumonia within 3 months prior to screening. 12. Patient with current rheumatologic conditions. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment. 13. Patients with neutropenia <1000 unit of measure? 14. Patients participating or planning to participate in the next 6 months in interventional research trials. Exceptions can be made per PI discretion. 15. Patients who have received systemic corticosteroids therapy for 1 week or more over the past 2 months. 16. Patient with an allergy to Vancomycin or Neomycin

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rima Rachid
  • Collaborator
    • University of Minnesota
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Rima Rachid, Attending Physician, Division of Immunology – Boston Children’s Hospital
  • Overall Official(s)
    • Rima Rachid, Principal Investigator, Boston Children’s Hospital
  • Overall Contact(s)
    • Angela Zhang, 617-919-1566, Angela.Zhang@childrens.harvard.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.